While attractive, IDH-mutant CH is rare and far less common than CH-associated mutations in DNMT3A, TET2, or ASXL1. As additional targeted therapies are shown to be efficacious and safe in MN, more therapeutic options for CCUS and other high-risk forms of CH will emerge. This evidence concerns the gene DNMT3A and cyclic hematopoiesis.